E. Kon (Milano, IT)

Humanitas University Orthopaedic Surgery
Associated Professor Humanitas University; Milan; Orthopedic surgeon; Center of Functional and Biological Reconstruction of the knee; Humanitas Research Hospital; Milan. Professor First Moscow State Medical University (Sechenov University); Moscow; Russia 1st Vice President of the International Cartilage Regeneration & Joint Preservation Society (ICRS). Until 2017 Director of Nano-Biotecnology Laboratory and orthopedic surgeon; Rizzoli Orthopedic Institute and Assistant Professor; University of Bologna; Coordinator of numerous research projects and clinical trials regarding biotechnology applications in orthopaedics; into the framework of Italian and European research. Author of over 180 scientific articles in peer-reviewed journals and over 30 chapters in textbooks in orthopedic surgery (H-index 65). Faculty of more than 400 society meetings all over Europe; Asia and America. Associated Editor of BMC Musculoskeletal Disorders Journal; International Orthopedics; Journal of Experimental Orthopedics and Joints. Reviewer for more than 20 Orthopaedics Journal. Travelling Fellow ESSKA/AOSSM European/North American Sports Medicine Traveling Fellowship; 2009 and ICRS Travelling Fellowship; North America; 2004 Winner of several awards as most cited and most downloaded publication 2011-2016 in Arthroscopy Journal; Leading article Knee Surgery Sports Traumatology Arthroscopy Journal; 2013 and 2016; Poster Award Cum Laude; ICRS World Congress; 2015 and 2013; Most cited publication 2009-2010 in American Journal of Sports Medicine; Scientific exhibit award of excellence AAOS Annual Meeting 2011

Presenter Of 7 Presentations

Extended Abstract (for invited Faculty only) Others

5.0.2 - ICRS Vision Lecture - To the Future...

Presentation Topic
Others
Date
12.04.2022
Lecture Time
17:10 - 17:20
Room
Potsdam 1
Session Type
Plenary Session
Extended Abstract (for invited Faculty only) Please select your topic

8.1.2 - Conservative Treatment

Presentation Topic
Please select your topic
Date
13.04.2022
Lecture Time
11:00 - 11:15
Room
Potsdam 1
Session Type
Special Session
Extended Abstract (for invited Faculty only) Joint Specific Cartilage Repair

9.1.3 - Best Practices: Agili-C™ Surgical Technique

Presentation Topic
Joint Specific Cartilage Repair
Date
13.04.2022
Lecture Time
12:30 - 12:45
Room
Potsdam 1
Session Type
Industry Satellite Symposium
Extended Abstract (for invited Faculty only) Meniscus

13.2.1 - All You Need to Know About Meniscus: Meniscus Discovery Series

Presentation Topic
Meniscus
Date
14.04.2022
Lecture Time
07:30 - 07:38
Room
Potsdam 3
Session Type
Morning Workshop
Podium Presentation Biomaterials and Scaffolds

18.1.2 - Effect of Patient’s Characteristics on Clinical Outcome Comparing Aragonite-Based Scaffold Implant vs Debridement/Microfractures

Presentation Topic
Biomaterials and Scaffolds
Date
14.04.2022
Lecture Time
14:24 - 14:33
Room
Bellevue
Session Type
Free Papers
Disclosure
Elizaveta Kon, CartiHeal, Consultant; Nir Altschuler, CartiHeal, Employee

Abstract

Purpose

Patient’s specific characteristics may play a role in determining clinical outcome after cartilage regenerative procedures. The objective of this analysis was to reveal if any correlation existed among patient’s characteristics and clinical outcome in the context of a RCT comparing an aragonite-based scaffold to debridement/microfractures for treating joint surface lesions.

Methods and Materials

A large RCT was performed in 26 medical centers, involving 167 subjects who underwent aragonite-based (Agili-C™, CartiHeal Ltd., Israel) scaffold implantation and 84 subjects who underwent arthroscopic debridement/microfractures (control) for the treatment of chondral/osteochondral knee defects. For each treatment group, the influence of age, sex, BMI, previous ligament reconstruction, pre-injury activity level and smoking history were analyzed to detect if a correlation existed in regards to the clinical outcome, up to the final evaluation at 24 months’ follow-up.

Results

Scaffold superiority over debridement/microfractures was confirmed across all sub-groups and covariates analysis. In the scaffold group, comparable clinical benefit was obtained in subjects younger or older than 50yy (p<0.0001). Moreover, the regenerative approach provided satisfactory outcome even in subjects older than 65yy, although their number in the present cohort was small. Differences between scaffold and control groups were much higher in females than in males, suggesting that the former, who usually present poorer prognosis after cartilage surgery, are good candidates for the aragonite-based implant. In the scaffold group, subjects with BMI lower or higher than 30 presented similar KOOS score improvement at 24 months, with better results than control even in obese patients. Previous ligament reconstruction and smoking history did not negatively influence the scaffold group. Considering pre-injury activity level, the comparison revealed particular advantage for the scaffold in non-active subjects.

Conclusion

The aragonite-based scaffold’s superiority over control was confirmed across all subgroups and covariates. Its efficacy was not influenced by sex, age, BMI, previous ligament surgery, smoking history and activity level.

Collapse
Podium Presentation Osteoarthritis

24.3.9 - Five Year Follow-Up of a Single, Intra-Articular Injection of Autologous Protein Solution in Patients with Knee OA (Progress II)

Presentation Topic
Osteoarthritis
Date
15.04.2022
Lecture Time
11:45 - 11:54
Room
Bellevue
Session Type
Free Papers
Disclosure
This study was sponsored by Zimmer Biomet.

Abstract

Purpose

The purpose of this study is to evaluate long term follow-up of single injection of nSTRIDE® APS for the treatment of unilateral knee osteoarthritis (NCT02138890).

Methods and Materials

Forty-six patients underwent a 2:1 randomization process to either one single injection of APS(n=31) or salin (n=15). APS was prepared with the nSTRIDE APS Kit (Zimmer Biomet). Data up to the 3 year follow up were previously published(1). The APS cohort was asked to participate in unblinded 60-month follow-up and the saline patients were offered cross-over after 12 months and were similarly followed. Efficacy endpoints (WOMAC LK 3.1, KOOS, and VAS) were measured as a change from baseline to each time point. Data is presented as mean ± SD. Missing data was calculated as baseline carried forward(BLCF) for subjects that had exited the trial for knee OA pain.

Results

At the final follow-up for the study (60 months), 17 of the original 31 randomized to APS and 6 of the original 15 saline/crossover remained in the study. The Kaplan-Meier curve for subjects exiting for knee-related events demonstrate a 0.64 survivorship probability[95% CI 0.463,0.820](Figure 1). Using the BLCF method, the APS cohort had a mean WOMAC pain percent improvement from baseline of 64.8±29.5% at 1 year(p<0.0001), 50.4±42.1% at 3 years(p<0.0001), and 39.0±41.2% at 5 years(p<0.0001). For the subjects that accepted crossover after 1 year, the WOMAC pain improvement was 45.5±33.3% at time of crossover(p=0.0002), 44.0±37.6% at 3 years(p=0.0008), and 24.6±33.7% at 5 years(p=0.028).

figure 1 progress ii.jpg

Conclusion

All in all, treatment with a single, intra-articular injection of APS in subjects with knee osteoarthritis has shown long-lasting pain and function relief and indicates of the long-term durability APS for knee osteoarthritis.

[1]Kon et al. AJSM;2020;48(11):2703-2710.

Collapse
Poster Osteoarthritis

P150 - A Two-Phase RCT Comparing Autologous Protein Solution with Hyaluronic Acid Intra Articular Injections in Patients with Knee OA (PROGRESS V)

Presentation Topic
Osteoarthritis
Date
13.04.2022
Lecture Time
09:30 - 09:30
Room
Exhibition Foyer
Session Name
7.3 - Poster Viewing / Coffee Break / Exhibition
Session Type
Poster Session
Disclosure
This study was sponsored by Zimmer Biomet.

Abstract

Purpose

The purpose of this study is to compare the safety and effectiveness of a single injection of nSTRIDE® APS and Synvisc-One® Hyaluronic Acid for unilateral knee osteoarthritis(NCT03182374).

Methods and Materials

Subjects with knee OA Kellgren-Lawrence 2-4(n=252) were randomized 1:1 to receive a single injection of APS or HA. Endpoints included WOMAC pain, function, stiffness, and quality of life as well as safety and change in X-ray. After 12 months, subjects were allowed a blinded second injection choice(no injection, same injection, or crossover). This analysis follows subjects for 24 months.

Results

Nine APS subjects and 16 HA subjects exited early (prior to 12-months) due to issues related to knee OA. Both groups had a significant improvement in pain from baseline with no significant difference between groups(APS:41.1 ± 34.6%;HA:40.4 ± 33.5%). Both groups had similar improvements in function, stiffness, NRS pain, EQ-5D, and responder rates. Use of restricted medication for knee OA was 8.8% in the APS group and 12.2% in the HA group at their 12-month visit. There was no difference in overall adverse event reporting between groups. At the 24-month time point, subjects that chose no second injection maintained similar pain reduction as their 12-month time point(change 0.4 for APS and -0.7 for HA). APS subjects requesting a second “same” injection had a statically significant improvement in pain at 24 months(change -1.0;p=0.03) while the HA subjects receiving the “same” second injection did not significantly improve(change -1.1;p=0.09). Subjects receiving cross over treatment did not show significant improvement from 12-month pain scores(change -1.5 for APS and -0.2 for HA). Of the original 41 subjects selecting crossover treatment, 16 rated no preference between injections while 18 preferred APS and 7 preferred HA(p=0.0417).

Conclusion

Both APS and HA improved knee OA symptoms at 12-months post injection. Subjects receiving a second APS injection statistically improved from 12 to 24 months.

Collapse

Moderator Of 5 Sessions

Potsdam 1 Industry Satellite Symposium
Potsdam 3 Morning Workshop
Session Type
Morning Workshop
Date
14.04.2022
Time
07:30 - 08:15
Room
Potsdam 3
CME Evaluation
Bellevue Plenary Session
Session Type
Plenary Session
Date
14.04.2022
Time
17:30 - 18:30
Room
Bellevue
Session Description
All ICRS members, present in Berlin are expected to attend the ICRS General Member’s Assembly. Retired Members and Corporate Members have no right to vote but are most welcome to attend. It is of utmost importance that as many members as possible attend this important meeting and take part in decision-making and approval processes of our association.
Potsdam 1 Plenary Session
Session Type
Plenary Session
Date
15.04.2022
Time
08:30 - 09:30
Room
Potsdam 1
Session Description
Worldwide experts discuss the advances, obstacles, and regulatory issues in clinical therapy, osteoarthritis treatments, and translational gene therapy.
Session Learning Objective
  1. Participants will learn about the feasibility and challenges of developing a novel clinical trial based on preclinical results.
CME Evaluation

Meeting Participant Of

Glienicke Board Room (18) ICRS Committee Meeting

Cartilage Executive Office - General Assembly

Session Type
ICRS Committee Meeting
Date
13.04.2022
Time
18:00 - 18:20
Room
Glienicke Board Room (18)
Glienicke Board Room (18) ICRS Committee Meeting

Executive Board Meeting

Session Type
ICRS Committee Meeting
Date
12.04.2022
Time
08:00 - 09:45
Room
Glienicke Board Room (18)
Session Description
Only for invited Committee Members
Bellevue Plenary Session
Session Type
Plenary Session
Date
14.04.2022
Time
17:30 - 18:30
Room
Bellevue
Session Description
All ICRS members, present in Berlin are expected to attend the ICRS General Member’s Assembly. Retired Members and Corporate Members have no right to vote but are most welcome to attend. It is of utmost importance that as many members as possible attend this important meeting and take part in decision-making and approval processes of our association.